Siddhartha P. Kar, Emily Adler, Jonathan Tyrer, et al. Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. Br J Cancer. 2017 Feb 14;116(4):524-535
Buchanan DD, Clendenning M, Rosty C,, Eriksen SV, Walsh MD, Walters RJ, Thibodeau SN, Stewart J, Preston S, Win AK, Flander L, et al. Tumour testing to identify Lynch syndrome in two Australian colorectal cancer cohorts. J Gastroenterol Hepatol. 2017 Feb;32(2):427-438
Melissa A. Yow, Sepehr N. Tabrizi, Gianluca Severi, Damien M. Bolton, John Pedersen, Australian Prostate Cancer BioResource, Graham G. Giles and Melissa C. Southey. Characterisation of microbial communities within aggressive prostate cancer tissues. Infect Agent Cancer 2017 Jan 13;12:4.
FitzGerald LM, Naeem H, Makalic E, Schmidt DF, Dowty JG, Joo JE, Jung CH, Bassett JK, Dugue PA, Chung J, Lonie A, Milne RL, et al. Genome-wide measures of peripheral blood DNA methylation and prostate cancer risk in a prospective nested case-control study. 2017 Apr;77(5):471-478
Maryam Mahmoodi, Tu Nguyen-Dumont, Fleur Hammet, Bernard J. Pope, Daniel J. Park, Melissa C. Southey, John Darlow, Fiona Bruinsma, Ingrid Winship. Mutation screening of ACKR3 and COPS8 in kidney cancer cases from the CONFIRM study. Fam Cancer 2017 Jan 6. [Epub ahead of print].
Philip J Law, Sonja I Berndt, Helen E Speedy, Nicola J Camp, Georgina P Sava, Christine F Skibola, Amy Holroyd, Joseph Vijai, et al. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukemia. Nat Commun. 2017 Feb 6;8:14175.
Rainer Fagerholm, Sofia Khan, Marjanka K. Schmidt, Montserrat García-Closas, Päivi Heikkilä, Jani Saarela, Jonathan Beesley, et al. TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. Oncotarget. 2017 Feb 5.
Logan C. Walker, John F. Pearson, George A.R. Wiggins, Graham G. Giles, John L. Hopper, Melissa C. Southey. Increased genomic burden of germline copy number variants is associated with early onset breast cancer: Australian Breast Cancer Family Registry. Breast Cancer Res 2017 Mar 16;19(1):30.
Hui-Chen Wu, Melissa C Southey, Hanina Hibshoosh, Regina M. Santella, Mary Beth Terry. DNA Methylation in Breast Tumor from High-risk Women in the Breast Cancer Family Registry. Anticancer Res. 2017 Feb;37(2):659-664.
Shuai Li, Ee Ming Wong, Melissa C Southey, and John L Hopper. Association between DNA methylation in SOCS3 and body mass index might be due to familial confounding. Int J Obes (Lond). 2017 2017 Mar 21. [Epub ahead of print]
Hermela Shimelis, Romy L.S. Mesman, Catharina Von Nicolai, Asa Ehlen, Lucia Guidugli, Charlotte Martin, et al. BRCA2 hypomorphic missense variants confer moderate risks of breast cancer. Cancer Res. 2017 Mar 10. pii: canres.2568.2016. [Epub ahead of print]
Li H, Feng B, Miron A, Chen X, Beesley J, Bimeh E, Barrowdale D, John EM, Daly MB, Andrulis IL, Buys SS, Kraft P; kConFab investigators, et al. Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab. Genet Med. 2016 2017 Jan;19(1):30-35
Baglietto L, Ponzi E, Haycock P, Hodge A, Bianca Assumma M, Jung CH, Chung J, Fasanelli F, Guida F, Campanella G, Chadeau-Hyam M, et al. DNA methylation changes measured in pre-diagnostic peripheral blood samples are associated with smoking and lung cancer risk. Int J Cancer. 2017 Jan 1;140(1):50-61
Hamdi Y, Soucy P, Kuchenbaeker KB, Pastinen T, Droit A, Lemaçon A, Adlard J, Aittomäki K, Andrulis IL, Arason A, Arnold N, Arun BK, et al. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat. 2017 Jan;161(1):117-134
Harindra Jayasekara, Robert J. MacInnis, Elizabeth J. Williamson, Allison M. Hodge, Mark Clendenning, Christophe Rosty, et al. Lifetime alcohol intake is associated with an increased risk of KRAS+ and BRAF-/KRAS- but not BRAF+ colorectal cancer. Int J Cancer 2017 Apr 1;140(7):1485-1493